New recommendations prioritise multiparametric MRI, safer transperineal biopsy, and earlier escalation for high-risk prostate-specific antigen relapse.

Checking PSA levels following treatment is crucial among patients with nonmetastatic, unfavorable risk prostate cancer, according to the co-author of a recent study. Prostate-specific antigen (PSA) ...

The most common screening test for prostate cancer so often returns a false positive result that it's no longer recommended for men older than 70, and it's offered as a personal choice for younger men ...

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma Factors correlated with ...

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate ...

Investigators evaluated the benefit of leuprorelin immediately after radical prostatectomy for prostate cancer in patients ...

Prostate cancer screening is essential for early detection, especially in high-risk groups like men over 50, African Americans, and those with a family history. Routine screening, including PSA tests ...

In tandem with September’s Prostate Cancer Awareness Month, Cleveland Diagnostics is kicking off a campaign to boost awareness of and education around screening tests for the disease. The flagship ...

Doctors began testing PSA levels in the 1980s to monitor diagnosed cancers. By the early 1990s, researchers promoted it for ...

− Post-hoc analysis from Blue Earth Diagnostics’ Phase 3 SPOTLIGHT trial provides data about treatment planning, particularly when curative salvage therapy is considered – MONROE TOWNSHIP, N.J. & ...